Objective-The aim of this study was to correlate the expression of InsP 3 R subtypes in native vascular and visceral myocytes with specific Ca 2ϩ -signaling patterns. Methods and Results-By Western blot and immunostaining, we showed that rat portal vein expressed InsP 3 R1 and InsP 3 R2 but not InsP 3 R3, whereas rat ureter expressed InsP 3 R1 and InsP 3 R3 but not InsP 3 R2. Acetylcholine induced single Ca 2ϩ responses in all ureteric myocytes but only in 50% of vascular myocytes. In the remaining vascular myocytes, the first transient peak was followed by Ca 2ϩ oscillations. By correlating Ca 2ϩ signals and immunostaining, we revealed that oscillating vascular cells expressed both InsP 3 R1 and InsP 3 R2 whereas nonoscillating vascular cells expressed only InsP 3 R1. Acetylcholine-induced oscillations were not affected by inhibitors of ryanodine receptors, Ca 2ϩ -ATPases, Ca 2ϩ influx, and mitochondrial Ca 2ϩ uniporter but were inhibited by intracellular infusion of heparin.
S timulation of plasma membrane receptors results generally in the generation of inositol 1,4,5-trisphosphate (InsP 3 ) via the activation of phospholipase C. InsP 3 releases Ca 2ϩ from intracellular stores by binding to InsP 3 receptors (InsP 3 Rs), which form tetrameric InsP 3 -gated Ca 2ϩ release channels. 1 Molecular cloning studies have revealed that there are at least 3 subtypes of InsP 3 Rs derived from distinct genes, designated as subtype 1 (InsP 3 R1), subtype 2 (InsP 3 R2), and subtype 3 (InsP 3 R3). [2] [3] [4] Multiple subtypes of InsP 3 Rs may be expressed in different cell types and form both homotetramers and heterotetramers. 5, 6 Therefore, expression of different InsP 3 Rs may support the generation of specific Ca 2ϩ responses. Recent studies using incorporation of InsP 3 Rs into lipid bilayers and overexpression of recombinant InsP 3 Rs have suggested that the 3 InsP 3 R subtypes may be differentially regulated by InsP 3 and Ca 2ϩ , calmodulin, ATP, and phosphorylation. [7] [8] [9] [10] [11] [12] In genetically engineered DT40 B cells that express either a single or a combination of InsP 3 R subtypes, distinct patterns of Ca 2ϩ signals have been reported. 13 However, expression of InsP 3 R subtypes have not been analyzed in different native cells under equivalent experimen-tal conditions, and it has not been demonstrated that the differential expression of InsP 3 R subtypes may be responsible for the different Ca 2ϩ signal patterns recorded in situ.
The aim of the present study was to correlate the functional expression of InsP 3 R subtypes with specific Ca 2ϩ -signaling patterns in native vascular and visceral smooth muscle cells. Our results show that the functional InsP 3 R subtypes expressed in rat portal vein and ureteric myocytes differ and may support different acetylcholine-induced Ca 2ϩ responses, ie, Ca 2ϩ oscillations and single Ca 2ϩ responses.
Methods

Cell Preparation
The investigation conforms with the European Community and French guiding principles in the care and use of animals. Authorization to perform animal experiments was obtained from the French Ministère de l'Agriculture et de la Pêche.
Wistar rats (150 to 170 g) were killed by cervical dislocation. Isolated myocytes were obtained from portal vein and ureter by enzymatic dispersion, as previously described. 14 Cells were seeded on glass slides in physiological solution and maintained in short-term primary culture in medium M199 containing FCS (2% for portal vein myocytes and 5% for ureteric myocytes), 2 mmol/L glutamine, 1 mmol/L pyruvate, 20 U/mL penicillin, and 20 g/mL streptomycin; they were kept in an incubator gassed with 95% air and 5% CO 2 at 37°C and used either within 20 to 30 hours or within 2 to 4 days for cells injected with the antisense oligonucleotides.
Microinjection of Oligonucleotides
Phosphorothioate antisense oligonucleotides (denoted with the prefix "as") used in the present study were designed on the known cloned InsP 3 R sequences deposited in the GenBank sequence database with Lasergene software (DNASTAR). Sequences of all 3 InsP 3 R cDNAs were aligned with each other, and specific antisense oligonucleotide sequences were chosen in the region of the cDNA of interest, completely different from the sequences of the 2 other InsP 3 R subtypes. Then antisense sequences displaying putative binding to any other mammalian sequences deposited in GenBank were discarded. Oligonucleotides were injected into the nuclei of myocytes by a manual injection system (Eppendorf). Intranuclear oligonucleotide injection with Femtotips II (Eppendorf) was performed as previously described. 15 The myocytes were then cultured for 2 to 4 days in culture medium, and the glass slides were transferred into the perfusion chamber for physiological experiments. The sequence of asInsP 3 R1 is ATCTGTTGTACTGTTGGCC, corresponding to nucleotides 566 to 584 of cDNA; that of asInsP 3 R2 is TATTTCA-CAATTTCTCC, corresponding to nucleotides 580 to 596 of InsP 3 R2 cDNA; and that of InsP 3 R3 is TGTGCAGAAGCTGAATCA, corresponding to nucleotides 494 to 513 of InsP 3 R3 cDNA.
Western Blot Analysis
Western blot analyses of rat tissue extracts and COS-1 cells (50 g protein) were performed as previously described. 16 
Fluorescence Measurements
Measurements of [Ca 2ϩ ] i were performed with an indo-1 setup, as described elsewhere. 14 Cells were either preloaded with the membrane-permeant indo-1 AM (1 mol/L) for 30 minutes or 50 mol/L indo-1 was added to the pipette solution and entered the cells after establishment of the whole-cell recording mode. [Ca 2ϩ ] i was estimated from the 405/480-nm fluorescence ratio using a calibration determined within cells. 14 All measurements were made at 25Ϯ1°C. Voltage clamp was made with a standard patch-clamp technique using a List EPC-7 patch-clamp amplifier (Darmstadt-Eberstadt). Patch pipettes had resistances of 3 to 4 M⍀. Anti-InsP 3 R1, anti-InsP 3 R2, and anti-InsP 3 R3 antibodies were added to the pipette solution to allow dialysis of the cell after a breakthrough in whole-cell recording mode for at least 5 minutes, a time longer than that expected for diffusion of substances in solution. 17
InsP 3 R Immunostaining
Myocytes were washed with PBS, fixed with 4% (vol/vol) formaldehyde and 0.5% glutaraldehyde for 10 minutes at room temperature, and permeabilized in PBS containing 3% FCS and 1 mg/mL of saponin for 20 minutes. Cells were incubated with PBS, saponin (1 mg/mL), and anti-InsP 3 R antibody (1 g/mL) overnight at 4°C. Then cells were washed (4ϫ5 minutes) and incubated with the appropriate secondary antibody conjugated to fluorescein-isothiocyanate during 45 minutes at room temperature. After washing in PBS, cells were mounted in Vectashield (Valbiotech). Images of the stained cells were obtained with a confocal microscope (Bio-Rad MRC 1024, Bio-Rad), and fluorescence was estimated by gray level analysis using IDL software (RSI) in 0.5-m confocal sections. On each cell, fluorescence was acquired from a z-series analysis (20Ϯ5 sections) using Lasersharp software (Bio-Rad) and expressed by volume unit. Cells were compared by keeping acquisition parameters (such as gray scale, exposure time, iris aperture, gain, and laser power) constant. A similar protocol was applied to portal vein strips (longitudinal muscle) except that anti-InsP 3 R1 (Affinity BioReagents) and anti-InsP 3 R2 (Santa Cruz Biotechnology) antibodies were conjugated to Alexa 488 and Alexa 568 secondary antibodies, respectively.
Solutions
The physiological solution contained (in mmol/L) NaCl 130, KCl 5.6, MgCl 2 1, CaCl 2 2, glucose 11, and HEPES 10, pH 7.4, with NaOH. The basic pipette solution contained (in mmol/L) CsCl 130 and HEPES 10, pH 7.3, with CsOH. Acetylcholine and active compounds were applied to the recorded cell by pressure ejection for the period indicated on the records.
Chemicals and Drugs
Collagenase was obtained from Worthington. M199 medium, streptomycin, penicillin, glutamine, and pyruvate were from Invitrogen). FCS was from BioMedia. Indo-1, indo-1 AM, and the mouse monoclonal anti-RYR antibody (559279) were from Calbiochem, Meudon, France. Anti-InsP 3 R1, anti-InsP 3 R2, and anti-InsP 3 R3 antibodies (SC6093, SC7278, and SC7277) were from Santa Cruz Biotechnology (Santa Cruz, Calif), from Affinity BioReagents (anti-InsP 3 R1 antibody, COGER, Paris, France), from AbCys (anti-InsP 3 R2 antibody, Valbiotech), and from Transduction Laboratories (anti-InsP 3 R3 antibody, BD Sciences, Le Pont de Claix, France). Alexa 488 and Alexa 568 secondary antibodies were from Molecular Probes (Eugene, Ore). Anti-PCNA (proliferating cell nuclear antigen) antibody was from Chemicon (Temecula, Calif). All other products were from Sigma.
Data Analysis
Data are expressed as meanϮSEM; n represents the number of cells or experiments. Significance was tested by means of paired Student's t test when cells were their own control; otherwise, unpaired test was used. PϽ0.05 was considered significant.
Results
Ca 2؉ Responses Evoked by Acetylcholine
In portal vein myocytes, application of 1 mol/L acetylcholine (ACh) for 30 seconds induced 2 types of Ca 2ϩ responses. In 51% of cells (138 of 270 cells, 18 dissociations), ACh initiated a Ca 2ϩ peak that was followed by regenerative oscillations ( Figure 1A ). The amplitude of the first response reached 218Ϯ9 nmol/L from a resting level of 66Ϯ11 nmol/L (nϭ138). The amplitude of oscillations varied strongly, but the frequency of oscillations was reproducible independently of the duration of ACh applications (4.0Ϯ0.4 oscillations/ min, nϭ138). Although the percentage of oscillating cells was similar in the ACh concentration range from 1 nmol/L to 10 mol/L, the highest and more reproducible frequency of oscillations was obtained at 1 mol/L ACh (nϭ138), so that the following experiments were performed with this ACh concentration. The nonoscillating cells (49%) responded by single Ca 2ϩ responses ( Figure 1A ). On application of ACh, the peak response reached 198Ϯ10 nmol/L from a resting level of 67Ϯ9 nmol/L (nϭ132) and was followed by a sustained plateau of 50Ϯ25 nmol/L (nϭ132). It is noteworthy that the duration at half-maximal amplitude of the first Ca 2ϩ peak in oscillating cells (2.62Ϯ0.22 seconds, nϭ138) was smaller than that of single Ca 2ϩ transients in nonoscillating cells (6.74Ϯ0.62 seconds, nϭ132). Similarly, application of noradrenaline (0.1 to 10 mol/L) induced both Ca 2ϩ oscillations and single Ca 2ϩ transients in vascular myocytes (nϭ64). In contrast, in ureteric myocytes, Ca 2ϩ oscillations were never observed after application of 0.1 to 10 mol/L ACh (0 of 125 cells tested, 6 dissociations). As shown in Figure 1A , the amplitude of the transient Ca 2ϩ response evoked by 1 mol/L ACh was 368Ϯ17 nmol/L from a resting level of 72Ϯ9 nmol/L (nϭ92). This Ca 2ϩ peak was followed by a sustained plateau of 41Ϯ15 nmol/L (nϭ92).
Effects of different pharmacological substances and external ion solutions were tested on both amplitude (first Ca 2ϩ peak) and frequency of Ca 2ϩ oscillations induced by 1 mol/L ACh in vascular myocytes (Table) . Ca 2ϩ oscillation frequency was not affected after removal of external Ca 2ϩ for 30 seconds (in Ca 2ϩ -free solution containing 0.5 mmol/L EGTA), but the responses decreased in amplitude within 3 to 4 minutes as a consequence of the rapid depletion of the intracellular Ca 2ϩ store. Both amplitude of the first AChinduced Ca 2ϩ peak and frequency of oscillations were not significantly affected in the presence of 1 mol/L oxodipine (a specific inhibitor of voltage-dependent Ca 2ϩ channels) or 1 mol/L RU-360 (a selective inhibitor of the mitochondrial Ca 2ϩ uniporter 18 ). Although 10 mol/L ryanodine or 10 g/mL anti-ryanodine receptor antibody (inhibitors of ryanodine-sensitive Ca 2ϩ release channels 19 ) had no effect on Ca 2ϩ oscillation frequency, they decreased the amplitude of the Ca 2ϩ peak, as previously reported. 19 Depletion of the Ca 2ϩ store can be modulated by thapsigargin (a Ca 2ϩ -ATPase inhibitor). Different concentrations of thapsigargin were applied for 1 minute before testing the effects of 1 mol/L ACh. Thapsigargin inhibited in a concentration-dependent manner the ACh-induced Ca 2ϩ responses ( Figure 1B ). Complete inhibition was obtained with 10 mol/L thapsigargin, indicating that the store was empty. At 50 nmol/L, thapsigargin partially depleted the Ca 2ϩ store, because the first AChinduced Ca 2ϩ peak was decreased by approximately 50% ( Figure 1B ). Under these conditions, the number of cells producing Ca 2ϩ oscillations in response to ACh (9 of 17 cells tested) and the frequency of Ca 2ϩ oscillations were not significantly different from those obtained in control conditions (Table, Figure 1C ). However, a second application of ACh 5 minutes later was ineffective, as expected when the agonist-sensitive Ca 2ϩ store was completely depleted. Finally, intracellular application of 1 mg/mL heparin (an inhibitor of InsP 3 Rs) for 5 minutes suppressed the ACh-induced Ca 2ϩ responses in both vascular (nϭ14) and ureteric (nϭ12) myocytes. These results indicate that the ACh-mediated Ca 2ϩ release occurs from the sarcoplasmic reticulum and that Ca 2ϩ oscillations can be obtained from a partially depleted Ca 2ϩ store.
To check the possibility that the capacitative Ca 2ϩ entry could be different in the 2 types of vascular myocytes, Ca 2ϩ entry was stimulated either by a pathway involving a G qcoupled receptor (ACh) or by thapsigargin in cells identified ACh (1 mol/L) was applied 30 seconds after removal of external Ca 2ϩ , 1 minute after application of thapsigargin (50 nmol/L), 5 minutes after application of oxodipine (1 mol/L), and 15 minutes after application of RU-360 (1 mol/L) or ryanodine (10 mol/L). Anti-ryanodine receptor antibody (10 g/mL) was applied intracellularly through the patch pipette for 5 minutes and cells were held at Ϫ50 mV. Values are meanϮSEM for 9 to 19 oscillating nonpatched cells from 4 dissociations or for 5 oscillating cells held at Ϫ50 mV from 2 dissociations. osc indicates oscillations. *Values significantly different from those obtained in control conditions. as oscillating or nonoscillating during previous applications of ACh. After complete depletion of the Ca 2ϩ store by applications of 10 mol/L ACh or 10 mol/L thapsigargin in Ca 2ϩ -free 0.5 mmol/L EGTA-containing solution, readmission of 2 mmol/L external Ca 2ϩ caused a transient and significant increase in [Ca 2ϩ ] i . 20 In oscillating cells, peak Ca 2ϩ responses activated by ACh and by store depletion were 98Ϯ17 nmol/L (nϭ17) and 106Ϯ11 nmol/L (nϭ18), respectively, whereas in nonoscillating cells, they were 100Ϯ14 nmol/L (nϭ19) and 101Ϯ14 nmol/L (nϭ43), respectively. In addition, the Ca 2ϩ loading of the store was assessed by applications of 10 mmol/L caffeine after complete refilling of the Ca 2ϩ store in 2 mmol/L external Ca 2ϩ for 15 minutes. Peak amplitudes of caffeine-induced Ca 2ϩ responses were not significantly different in oscillating (183Ϯ19 nmol/L, nϭ18) and nonoscillating (210Ϯ21 nmol/L, nϭ19) cells. Taken together, these results indicate that ACh-induced Ca 2ϩ oscillations in vascular myocytes depend only on Ca 2ϩ release from the sarcoplasmic reticulum through activation of InsP 3 Rs and that both Ca 2ϩ content of the intracellular store and capacitative Ca 2ϩ entry were not different in oscillating and nonoscillating vascular myocytes.
Effects of External Ca 2؉ , Inhibitors of Ca 2؉ Channels, and Ca 2؉ Pumps on Ca 2؉ Oscillations Evoked by 1 mol/L ACh in Portal Vein Myocytes
Expression of InsP 3 R Subtypes
Expression of InsP 3 R subtypes was examined by using specific antibodies directed against InsP 3 R1, InsP 3 R2, and InsP 3 R3 in rat portal vein and ureteric myocytes and in COS-1 cells. Western blot detection of InsP 3 R subtypes ( Figure 2A ) indicated that InsP 3 R1 and InsP 3 R2 were expressed in portal vein myocytes and InsP 3 R1 and InsP 3 R3 in ureteric myocytes. As previously reported, 21 COS-1 cells expressed InsP 3 R2 and InsP 3 R3 but not InsP 3 R1. The molecular weight of each subtype was determined in 3 different experiments and corresponded to that expected from primary sequences. 4 Immunodetection of InsP 3 R subtypes in confocal sections from ureteric and portal vein myocytes was performed with a second set of antibodies from Santa Cruz Biotechnology. With these antibodies, the binding sites were revealed with the same fluorescein-isothiocyanate-conjugated secondary antibody and the specificity was attested by the use of available antigenic peptides. Nonspecific fluorescence (NSF) was determined when specific anti-InsP 3 R antibody was preincubated with its antigenic peptide 1 hour before application of the immunostaining protocol. When the cell fluorescence obtained with the anti-InsP 3 R antibody was higher than NSF, the cell was considered as positive and specific fluorescence (F-NSF) could be estimated. The antigenic peptide for InsP 3 R1 blocked the ability of the anti-InsP 3 R1 antibody to bind to its target (nϭ41) but did not interfere with the activity of both anti-InsP 3 R2 and anti-InsP 3 R3 antibodies (nϭ41). Similarly, the antigenic peptides for InsP 3 R2 and InsP 3 R3 blocked the activity of the anti-InsP 3 R2 and anti-InsP 3 R3 antibodies, respectively, but did not interfere with the ability of the anti-InsP 3 R1 antibody to bind to its target (nϭ32). Figure 2B illustrates typical immunostainings obtained in portal vein myocytes from the same dissociation with each of the anti-InsP 3 R subtype antibodies. All of the cells were stained with the anti-InsP 3 R1 antibody ( Figure 2B ; please see Figure IA , available in the online data supplement at http://atvb.ahajournals.org). In contrast, no specific staining was obtained with the anti-InsP 3 R3 antibody. Staining with the anti-InsP 3 R2 antibody revealed that only a fraction of myocytes expressed InsP 3 R2 (7 of 15 cells; Figure 2B ; please see online Figure IA ). A similar distribution of cell fluorescence was obtained from 6 different dissociations (please see online Figure IB ), supporting the idea that all of the cells expressed InsP 3 R1 whereas approximately 50% of the cells expressed InsP 3 R2. Quantitatively, specific fluorescence with the anti-InsP 3 R1 antibody was observed in 271 of 288 vascular myocytes tested (6 dissociations), whereas specific InsP 3 R2 immunostaining was detected in 231 of 452 cells tested (6 dissociations) and InsP 3 R3 labeling was never observed (217 cells tested, 6 dissociations) (please see online Figure IC ). In ureteric myocytes, specific InsP 3 R1 and InsP 3 R3 immunostainings were detected ( Figure 2B ), respectively, in 74 and 71 of 78 cells (please see online Figure IC ), whereas InsP 3 R2 labeling was never observed (96 cells tested, 5 dissociations). In COS-1 cells, specific immunostaining was obtained for InsP 3 R2 and InsP 3 R3 (in 58 and 55 of 60 cells tested, respectively) whereas InsP 3 R1 staining was never observed (63 cells tested, 4 dissociations; please see online Figure IC ). Coimmunostainings in confocal sections of intact portal vein muscle revealed that InsP 3 R2 was not expressed in all of the myocytes compared with InsP 3 R1 ( Figure 2C) . These results confirm that immunostainings with the anti-InsP 3 R antibodies are specific for the corresponding InsP 3 R subtypes and reveal a differential expression of InsP 3 R subtypes in vascular and ureteric myocytes.
The fact that the InsP 3 R2 subtype was detected by immunostaining in approximately 50% of all of the vascular cells tested prompted us to verify the expression of InsP 3 R1 and InsP 3 R2 in myocytes showing either Ca 2ϩ oscillations or single Ca 2ϩ responses. We found that all of the oscillating vascular myocytes expressed both InsP 3 R1 and InsP 3 R2 (nϭ116; 5 dissociations), whereas the nonoscillating myocytes expressed only InsP 3 R1 (nϭ121; 5 dissociations).
Specific InsP 3 R Isoforms Required for Ca 2؉ Oscillations
To assess the role of InsP 3 R subtypes in Ca 2ϩ oscillations, we used both subtype-specific antibodies and inhibition of InsP 3 R subtypes by an antisense strategy. For the antibody experiments, the following protocol was performed. On each myocyte, ACh (1 mol/L) was first ejected in non-voltageclamped conditions to detect the oscillating cells, and the parameters of the Ca 2ϩ responses were measured. Then, voltage-clamp conditions were established and a second application of ACh was applied 5 minutes later on the same cells maintained at a holding potential of Ϫ50 mV. In portal vein myocytes, the peak Ca 2ϩ response corresponding to the first ACh application (in non-voltage-clamped cells) was 270Ϯ39 nmol/L from a resting [Ca 2ϩ ] i level of 66Ϯ8 nmol/L (nϭ19). The amplitude of the second ACh-induced Ca 2ϩ response (in voltage-clamped cells) was 225Ϯ21 nmol/L from a resting level of 69Ϯ9 nmol/L (nϭ19). Similarly, the mean frequency of Ca 2ϩ oscillations during the second application of ACh was 4.2Ϯ0.8 oscillations/min, not differ-ent from that obtained during the first application of ACh (4.0Ϯ0.8 oscillations/min, nϭ19). Therefore, this protocol was used to examine the role of the InsP 3 R subtypes on the ACh-induced Ca 2ϩ responses by infusing the cells through the patch pipette with the specific InsP 3 R subtype antibodies for 5 minutes.
We tested the anti-InsP 3 R antibodies in nonoscillating vascular cells expressing only InsP 3 R1 to determine the effective concentrations of these antibodies. In nonoscillating vascular cells, the single Ca 2ϩ responses were inhibited in a concentration-dependent manner by intracellular applications of the anti-InsP 3 R1 antibody with maximal inhibition obtained at 1 g/mL (please see online Figures IIA and IIB) , whereas both anti-InsP 3 R2 and anti-InsP 3 R3 antibodies had no significant effects at concentrations up to 10 g/mL (please see online Figures IIC and IID) . The inhibitory effect of the anti-InsP 3 R1 antibody is specific, as shown by the absence of effect of boiled (90°C for 30 minutes) anti-InsP 3 R1 antibody (see online Figure IIB ) or antibody preincubated with its antigenic peptide (not shown). In oscillating vascular myocytes, intracellular application of the anti-InsP 3 R1 antibody inhibited the amplitude of Ca 2ϩ peaks, but oscillations were detected in all the cells tested ( Figure 3A  and 3B) . Interestingly, in the presence of anti-InsP 3 R1 antibody, the frequency of Ca 2ϩ oscillations was not significantly affected (control, 4.1Ϯ0.5 oscillations/min; in the presence of the antibody, 3.9Ϯ0.4 oscillations/min; nϭ6). Intracellular applications of anti-InsP 3 R2 antibody inhibited both ampli- tude and generation of Ca 2ϩ oscillations with a maximal effect at 1 g/mL ( Figure 3C ). At 1 g/mL anti-InsP 3 R2 antibody, ACh was able to induce a single Ca 2ϩ peak without oscillation ( Figure 3A) . By contrast, the anti-InsP 3 R23 antibody (1 to 10 mol/L) had no effect on the ACh-induced Ca 2ϩ responses (not illustrated), in agreement with the absence of detection of InsP 3 R3 in vascular myocytes. Similar results were obtained with the anti-InsP 3 R antibodies from Santa Cruz Biotechnology (not shown).
Reverse transcriptase-polymerase chain reaction performed on RNA extracts prepared from rat portal vein and ureteric myocytes confirmed the expression of the different InsP 3 R subtypes, as identified by Western blotting. Therefore, we designed antisense oligonucleotides specifically targeting each InsP 3 R subtype. The time course of antisense oligonucleotides efficiency was determined by checking the ability of asInsP 3 R to inhibit the expression of InsP 3 R isoform and the amplitude of ACh-induced Ca 2ϩ responses in vascular myocytes. Immunostaining with the anti-InsP 3 R1 antibody was maximally decreased 2 days after nuclear injection of 10 mol/L asInsP 3 R1 in vascular myocytes located in a marked area of glass slides, whereas noninjected cells outside this marked area (used as controls) were normally immunostained (please see online Figure IIIA ). Recovery began the next day, and staining of injected cells returned to control 4 days after injection of asInsP 3 R1. Increasing asInsP 3 R1 concentration to 20 mol/L had no additional inhibitory effect on InsP 3 R1 staining (nϭ17). Based on this time scale, we verified that the Ca 2ϩ responses were maximally decreased 2 days after injection of asInsP 3 R1 plus asInsP 3 R2 (10 mol/L each) and recovery began the next day (please see online Figure IIIB ). Nonspecific effects of antisense oligonucleotides were detected only at concentrations higher than 50 mol/L (nϭ10). We also verified that each InsP 3 R subtype was specifically decreased by the corresponding asInsP 3 R 2 days after injection. Vascular myocytes injected with asInsP 3 R2 or asInsP 3 R3 were normally stained with the anti-InsP 3 R1 antibody (please see online Figure IIIC ). In cells injected with asInsP 3 R, staining with the anti-InsP 3 R2 antibody was strongly reduced in immunopositive cells, which represented approximately 50% of the cells examined (please see online Figure IIID ). In contrast, in asInsP 3 R1-and asInsP 3 R3-injected cells, stainings with the anti-InsP 3 R2 antibody were similar to those obtained in noninjected cells (please see online Figure IIID) . These results indicate that the antisense oligonucleotides were efficient and specific in inhibiting expression of InsP 3 R subtypes within 2 days after nuclear injection and that they could be used to study the role of each InsP 3 R subtype on ACh-induced Ca 2ϩ responses. In vascular myocytes injected with 10 mol/L asInsP 3 R1, the amplitude of the first Ca 2ϩ peak evoked by 1 mol/L ACh was reduced by approximately 50% compared with noninjected cells, but oscillations were observed in most of the cells tested (41 of 50 cells, Figure 4 ). In cells injected with asInsP 3 R2, the amplitude of the first Ca 2ϩ peak was slightly reduced, but the percentage of oscillating cells was strongly inhibited (7 of 72 cells). No effect on the Ca 2ϩ peak and the percentage of oscillating cells (26 of 50 cells) was observed in cells injected with asInsP 3 R3 ( Figures 4B and 4C) . The frequency of oscillations in asInsP 3 R1-injected cells (4.0Ϯ0.3 oscillations/min, nϭ41) was not different of that in noninjected cells (4.3Ϯ0.2 oscillations/min, nϭ82). All of the cells used induced large Ca 2ϩ responses when 10 mmol/L caffeine was added at the end of this protocol. Cell proliferation was not detected with the anti-PCNA antibody in both freshly dissociated and cultured vascular myocytes (nϭ250).
Taken together, these results suggest that Ca 2ϩ oscillations in vascular myocytes require the presence of InsP 3 R2 and that InsP 3 R1 alone or both InsP 3 R1 and InsP 3 R3 are unable to produce Ca 2ϩ oscillations in vascular and ureteric myocytes, respectively.
Discussion
The results of the present study establish the functional role of InsP 3 R subtypes in native smooth muscle cells in response to acetylcholine. We obtained evidence that endogenous expression of InsP 3 R2 was critical for Ca 2ϩ oscillations in rat portal vein myocytes, whereas endogenous expression of For studying the role of each InsP 3 R subtype in various smooth muscle cells, we used 2 complementary methods, ie, specific anti-InsP 3 R antibodies and antisense oligonucleotides, which specifically inhibited the expression of each InsP 3 R subtype. Specificity of the anti-InsP 3 R antibodies is based on the following observations: (1) in different cell types, Western blotting reveals a differential expression of InsP 3 Rs, indicating that the anti-InsP 3 R antibodies do not cross-react with the different InsP 3 R subtypes; (2) similar differential immunostainings were obtained in the same cells with these anti-InsP 3 R antibodies; (3) immunostaining for 1 anti-InsP 3 R antibody is blocked by the COOH-terminal antigenic peptide of this antibody but not by any other antigenic peptides; (4) in functional experiments, these antibodies neutralized by their antigenic peptides or by heating (95°C for 30 minutes) have no effect on ACh-induced Ca 2ϩ responses in 2 different smooth muscle cell types; and (5) the inhibitory effects of each anti-InsP 3 R antibody on the Ca 2ϩ responses are concentration-dependent, with a maximal effect of approximately 1 g/mL. For the antisense strategy, appropriate controls have been carried out to demonstrate the efficiency of antisense oligonucleotides. We evaluated the specificity of antisense oligonucleotides to reduce the expression of the InsP 3 R subtypes labeled with the specific antibodies by showing (1) the specific inhibition of the targeted InsP 3 R subtype by 1 given antisense oligonucleotide and the lack of effect of this antisense oligonucleotide on the other InsP 3 R subtypes; (2) the lack of effect of antisense oligonucleotides against InsP 3 R3 in myocytes that did not express this subtype; and (3) the reduction of the InsP 3 R-mediated Ca 2ϩ response produced by each effective oligonucleotide compared with the suppression of Ca 2ϩ response after injection of a mixture of oligonucleotides targeting the expressed InsP 3 R subtypes. Ca 2ϩ oscillations can be supported by different Ca 2ϩ channels and Ca 2ϩ stores. 14, [22] [23] [24] We showed that the pharmacological inhibition of the mitochondrial Ca 2ϩ uniporter, RYRs, voltage-gated Ca 2ϩ channels, and Ca 2ϩ influx had no effect on ACh-induced Ca 2ϩ oscillations in rat portal vein myocytes. Because inhibition of InsP 3 R2 by specific antibodies and antisense oligonucleotides suppressed these responses, InsP 3 R2 seems necessary to support the AChinduced Ca 2ϩ oscillations. In vascular myocytes, distribution of InsP 3 R2 has been found at the plasma membrane and associated with the nucleus in proliferating cells. 25, 26 We show that freshly dissociated and short-term cultured rat portal vein myocytes express InsP 3 R1 whereas only 50% of the cells express InsP 3 R2 and generate Ca 2ϩ oscillations. It is unlikely that these 2 populations of myocytes correspond to cells being in different states of development, because staining with the anti-PCNA antibody was not detected in freshly dissociated and short-term cultured myocytes. Immunostaining of intact vascular muscle revealed that both InsP 3 R1 and InsP 3 R2 were expressed and that some cells expressed only InsP 3 R1, confirming the results obtained in dissociated vascular myocytes.
Targeted gene knockouts of InsP 3 R subtypes in DT40 B cells have revealed that cells expressing different InsP 3 R subtypes may show distinct patterns of Ca 2ϩ signaling. 13 When expressed singly, activation of InsP 3 R1 or InsP 3 R3 triggers 1 or 2 Ca 2ϩ peaks, whereas activation of InsP 3 R2 supports long-lasting, regular Ca 2ϩ oscillations. 13 In native cells, such as hepatocytes, cardiac myocytes, and pancreatic islets that show Ca 2ϩ oscillations, [27] [28] [29] the presence of InsP 3 R has been demonstrated in separate experiments. 30 With specific antibodies and antisense oligonucleotides, we demonstrate that native vascular myocytes expressing only InsP 3 R2 may generate Ca 2ϩ oscillations of small amplitude, confirming the results obtained in DT40 B cells. In agreement with these data, in native cells that do not express InsP 3 R2, like A7r5 cells 31 or ureteric myocytes (the present study), InsP 3 Rmediated Ca 2ϩ oscillations have not been observed. Conversely, Ca 2ϩ oscillations were observed in cells expressing a high proportion of InsP 3 R2 (RBL-2H3 mast cells 32 ) or ex- pressing both InsP 3 R2 and InsP 3 R3 (NIH-3T3 cells 33 ). In HeLa cells that show Ca 2ϩ oscillations with a low expression of InsP 3 R2, 33 it has been shown that these oscillations are dependent on the extracellular Ca 2ϩ concentration, 34 suggesting that Ca 2ϩ influx may be involved in triggering Ca 2ϩ oscillations in these cells.
Our results support a model in which Ca 2ϩ oscillations depend on Ca 2ϩ release from the intracellular store through both InsP 3 R1 and InsP 3 R2. Because InsP 3 R1 alone is unable to trigger Ca 2ϩ oscillations, it is likely that the properties of InsP 3 R2 are critical for these oscillations. InsP 3 R2 has a higher InsP 3 sensitivity than InsP 3 R1. 13 In native cells expressing predominantly InsP 3 R2, a sustained inhibition is obtained by increasing [Ca 2ϩ ] i , 4 a result that is not found in studies using planar lipid bilayers. 35 In contrast, InsP 3 R1 inhibition by high [Ca 2ϩ ] i has been reported in both bilayers and native cells. 36 Because our preliminary experiments using GFP-PH PLC␦ expression indicate that the InsP 3 production in vascular myocytes does not oscillate in response to 1 mol/L ACh, we speculate that the Ca 2ϩ -dependent inhibition of InsP 3 R2 may be important in the rapid fall of [Ca 2ϩ ] i during the first peak, as revealed by the duration at half-maximal amplitude of the first Ca 2ϩ peak, which is shorter in oscillating cells than in nonoscillating cells. Because [Ca 2ϩ ] i decreases near basal value, InsP 3 R2 can reopen, and a second Ca 2ϩ peak is initiated with the concomitant participation of InsP 3 R1. The InsP 3 -and Ca 2ϩ -dependences of InsP 3 R1 and InsP 3 R2 are under investigation in native vascular myocytes, because intracellular accessory proteins can strongly modulate InsP 3 R activity. 36 The physiological role of InsP 3 R2 has not been previously examined in freshly dissociated and short-term cultured vascular myocytes. However, in agonist-stimulated adult cardiomyocytes, it has been reported that activation of InsP 3 R may trigger additional action potentials leading to arrhythmias. 37 Moreover, intracellular Ca 2ϩ oscillations have been shown to support spontaneous contractions during early stages of cardiomyogenesis, before complete expression of ion channels. 38 It is tempting to speculate that vascular myocytes expressing both InsP 3 R1 and InsP 3 R2 may function as pacemaker cells, initiating and modulating rhythmic electrical and mechanical activities in portal vein. We have previously shown that in these cells, InsP 3 is generated under basal conditions and that the InsP 3 production is strongly increased by neurotransmitters. 39 Because vascular myocytes are electrically coupled by gap junctions, a small fraction of pacemaker cells activated by the basal InsP 3 concentration may trigger the spontaneous contractile activity of the vessel. When neurotransmitters are delivered, the frequency of rhythmic contractions is strongly increased, 40 as expected from an increase in the InsP 3 production, which can stimulate Ca 2ϩ oscillations in all the cells expressing both InsP 3 R1 and InsP 3 R2.
In conclusion, the differential expression of InsP 3 R subtypes seems a determinant factor in the generation of specific Ca 2ϩ -signaling patterns in native smooth muscle cells.
